Patents Assigned to Kyorin Pharmaceuticals Co., Ltd.
-
Publication number: 20200237745Abstract: An aqueous drug in which the chemical decomposition of the compound represented by formula (1) or of a salt thereof is inhibited, and a method for producing said aqueous drug. An aqueous drug provided with: a solution (liquid A) that contains the compound represented by formula (1) or a salt thereof and that has a pH of 5.3 or less; and a dilution liquid (liquid B) that is mixed with the liquid A in order to prepare a solution to be administered.Type: ApplicationFiled: March 5, 2020Publication date: July 30, 2020Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Takahiro GOTO, Hitoshi KOZUKA, Mizuho SHIBATA
-
Patent number: 10696630Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: September 24, 2019Date of Patent: June 30, 2020Assignee: Kyorin Pharmaceuticals Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20200157607Abstract: The present invention provides a reciprocal-flow-type nucleic acid amplification device comprising: heaters capable of forming a denaturation temperature zone and an extension/annealing temperature zone; a fluorescence detector capable of detecting movement of a sample solution between the two temperature zones; a pair of liquid delivery mechanisms that allow the sample solution to move between the two temperature zones and that are configured to be open to atmospheric pressure when liquid delivery stops; a substrate on which the chip for nucleic acid amplification according to claim 2 can be placed; and a control mechanism that controls driving of each liquid delivery mechanism by receiving an electrical signal from the fluorescence detector relating to movement of the sample solution from the control mechanism; the device being capable of performing real-time PCR by measuring fluorescence intensity for each thermal cycle.Type: ApplicationFiled: February 5, 2020Publication date: May 21, 2020Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hidenori NAGAI, Shunsuke FURUTANI, Yoshihisa HAGIHARA, Yusuke FUCHIWAKI
-
Patent number: 10617684Abstract: An aqueous drug in which the chemical decomposition of the compound represented by formula (1) or of a salt thereof is inhibited, and a method for producing said aqueous drug. An aqueous drug provided with: a solution (liquid A) that contains the compound represented by formula (1) or a salt thereof and that has a pH of 5.3 or less; and a dilution liquid (liquid B) that is mixed with the liquid A in order to prepare a solution to be administered.Type: GrantFiled: June 2, 2016Date of Patent: April 14, 2020Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Takahiro Goto, Hitoshi Kozuka, Mizuho Shibata
-
Patent number: 10525058Abstract: The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: GrantFiled: May 26, 2016Date of Patent: January 7, 2020Assignee: KYORIN PHARMACEUTICAL CO., LTDInventors: Kiyoshi Fujii, Kentaro Umei, Hiroyasu Takahashi, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 10517851Abstract: A problem to be solved by the present invention is to provide a method for ameliorating pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria by finding a composition that enhances the antidiuretic action of vasopressin or a vasopressin V2 receptor agonist. As a result of the studies, it has been found that imidafenacin enhances the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, whereby the present invention has been completed. According to the present invention, a composition containing imidafenacin can enhance the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, making it possible to ameliorate pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria.Type: GrantFiled: December 22, 2016Date of Patent: December 31, 2019Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventor: Takanobu Yamazaki
-
Patent number: 10464891Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: February 7, 2019Date of Patent: November 5, 2019Assignee: Kyorin Pharmaceuticals Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Patent number: 10406149Abstract: A novel technique with which it is possible to suppress chemical degradation of a compound represented by general formula (1) or a salt thereof in an aqueous liquid formulation containing a compound represented by general formula (1) or a salt thereof. A method for suppressing the generation of a compound represented by general formula (2) or a salt thereof including containing a compound represented by general formula (1) or a salt thereof and a magnesium compound in an aqueous liquid formulation.Type: GrantFiled: June 2, 2016Date of Patent: September 10, 2019Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Wataru Minagawa, Hitoshi Kozuka, Mizuho Shibata, Takahiro Goto, Chifuyu Toriumi, Norihiro Kanayama
-
Patent number: 10252992Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: June 18, 2018Date of Patent: April 9, 2019Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20190076421Abstract: [Problem] The present invention pertains to a safer and more effective respiratory infection treating agent. [Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 13, 2018Publication date: March 14, 2019Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kota KUME, Hisao YOSHIDA, Hirotaka ANDO, Yuta TANAKA
-
Patent number: 10206917Abstract: An aqueous drug that contains the compound represented by formula (1) or a salt thereof and in which the precipitation and the chemical dissolution of the compound of formula (1) or of a salt thereof is inhibited. An aqueous drug containing: the compound represented by formula (1) or a salt thereof; and a magnesium compound. The aqueous drug has a pH of 5.8-6.9. The concentration of the compound represented by formula (1) is 3 mg/mL or more.Type: GrantFiled: June 2, 2016Date of Patent: February 19, 2019Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Takahiro Goto, Hitoshi Kozuka, Mizuho Shibata, Wataru Minagawa, Norihiro Kanayama, Chifuyu Toriumi
-
Patent number: 10154993Abstract: [Problem] To provide a novel pharmaceutical composition which can suppress delayed, release of the compound represented in general formula (1) or a salt thereof. [Solution] This solid pharmaceutical composition contains the compound represented in general formula (1), or a salt thereof, and a salting-out agent.Type: GrantFiled: October 23, 2015Date of Patent: December 18, 2018Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Uchida, Masataka Hanada, Yoshikazu Miyazaki
-
Publication number: 20180344700Abstract: A problem to be solved by the present invention is to provide a method for ameliorating pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria by finding a composition that enhances the antidiuretic action of vasopressin or a vasopressin V2 receptor agonist. As a result of the studies, it has been found that imidafenacin enhances the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, whereby the present invention has been completed. According to the present invention, a composition containing imidafenacin can enhance the antidiuretic action of vasopressin or the vasopressin V2 receptor agonist, making it possible to ameliorate pollakiuria and nocturia, in particular, nocturia caused by nocturnal polyuria.Type: ApplicationFiled: December 22, 2016Publication date: December 6, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventor: Takanobu YAMAZAKI
-
Publication number: 20180208552Abstract: The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: ApplicationFiled: May 26, 2016Publication date: July 26, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Hiroyasu TAKAHASHI, Hiroyuki WATANABE, Kiyoshi FUJII, Mitsuhito SHIBASAKI, Mikako KAWASHIMA, Megumi KAMIYA, Kohei OHATA
-
Publication number: 20180207153Abstract: The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative N represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.Type: ApplicationFiled: May 26, 2016Publication date: July 26, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Kiyoshi FUJII, Kentaro UMEI, Hiroyasu TAKAHASHI, Mitsuhito SHIBASAKI, Kohei OHATA
-
Patent number: 10029983Abstract: Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: October 3, 2017Date of Patent: July 24, 2018Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Hiroyasu Takahashi, Yoshifumi Saito, Kosuke Tsuda, Mitsuhito Shibasaki, Kohei Ohata
-
Publication number: 20180169088Abstract: An aqueous drug that contains the compound represented by formula (1) or a salt thereof and in which the precipitation and the chemical dissolution of the compound of formula (1) or of a salt thereof is inhibited. An aqueous drug containing: the compound represented by formula (1) or a salt thereof; and a magnesium compound. The aqueous drug has a pH of 5.8-6.9. The concentration of the compound represented by formula (1) is 3 mg/mL or more.Type: ApplicationFiled: June 2, 2016Publication date: June 21, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Takahiro GOTO, Hitoshi KOZUKA, Mizuho SHIBATA, Wataru MINAGAWA, Norihiro KANAYAMA, Chifuyu TORIUMI
-
Publication number: 20180153875Abstract: An aqueous drug in which the chemical decomposition of the compound represented by formula (1) or of a salt thereof is inhibited, and a method for producing said aqueous drug. An aqueous drug provided with: a solution (liquid A) that contains the compound represented by formula (1) or a salt thereof and that has a pH of 5.3 or less; and a dilution liquid (liquid B) that is mixed with the liquid A in order to prepare a solution to be administered.Type: ApplicationFiled: June 2, 2016Publication date: June 7, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Takahiro GOTO, Hitoshi KOZUKA, Mizuho SHIBATA
-
Publication number: 20180147199Abstract: A novel technique with which it is possible to suppress chemical degradation of a compound represented by general formula (1) or a salt thereof in an aqueous liquid formulation containing a compound represented by general formula (1) or a salt thereof. A method for suppressing the generation of a compound represented by general formula (2) or a salt thereof including containing a compound represented by general formula (1) or a salt thereof and a magnesium compound in an aqueous liquid formulation.Type: ApplicationFiled: June 2, 2016Publication date: May 31, 2018Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Wataru MINAGAWA, Hitoshi KOZUKA, Mizuho SHIBATA, Takahiro GOTO, Chifuyu TORIUMI, Norihiro KANAYAMA
-
Patent number: RE47785Abstract: Disclosed is a technique for improving the water solubility and storage stability of 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound (1)) that is safe and not only has a strong antibacterial action but also is effective for resistant bacteria for which conventional antibacterial agent are less effective. Crystals of the hydrochloride salt of the compound (1), crystals of the hydrochloride salt hydrate of the compound (1), and crystals of the methanesulfonate salt of the compound (1) are provided. In these crystals, decomposition due to influences of light is suppressed as compared to that in crystals of the compound (1) in free, and their storage stability is high. These crystals have higher solubility in water than the crystals of the compound (1) in free.Type: GrantFiled: May 2, 2018Date of Patent: December 31, 2019Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Ichiro Araya, Akinori Goto, Wataru Minagawa, Keiko Funada, Muneki Nagao